Authors
Emily E Vivio, Navya Kanuri, Joanna J Gilbertsen, Kelly Monroe, Neelendu Dey, Chien-Huan Chen, Alexandra M Gutierrez, Matthew A Ciorba
Publication date
2016/4/1
Journal
Journal of Crohn's and Colitis
Volume
10
Issue
4
Pages
402-409
Publisher
Oxford University Press
Description
Background and aims
Vedolizumab inhibits leucocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. This agent became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and UC (UC). The aim of this study was to assess the patterns of use, effectiveness and safety of vedolizumab in an inflammatory bowel disease (IBD) clinical practice.
Methods
Patients beginning vedolizumab were enrolled with informed consent. A prospective cohort was followed with laboratory, disease activity and quality-of-life assessments made during infusion visits up to week 14. Duration of vedolizumab use, mucosal healing and safety were analysed retrospectively for all patients not captured in the prospective component of this study.
Results
One hundred and two patients started …
Scholar articles
EE Vivio, N Kanuri, JJ Gilbertsen, K Monroe, N Dey… - Journal of Crohn's and Colitis, 2016